ANI Pharmaceuticals Stock (NASDAQ:ANIP)
Previous Close
$81.85
52W Range
$61.18 - $99.50
50D Avg
$79.72
200D Avg
$83.34
Market Cap
$1.86B
Avg Vol (3M)
$353.27K
Beta
0.44
Div Yield
-
ANIP Company Profile
ANI Pharmaceuticals, Inc. operates as a biopharmaceutical firm, concentrating on the development, production, and commercialization of both proprietary (branded) and unbranded (generic) prescription medications across the United States and Canada. The company's primary focus areas include manufacturing controlled substances, treatments for oncology, hormones and steroids, injectable drugs, and various other pharmaceutical preparations. Its robust manufacturing capabilities encompass a range of dosage forms, such as oral solid products, semi-solids, liquid formulations, and topical agents, as well as highly potent compounds. Furthermore, ANI Pharmaceuticals provides contract development and manufacturing services to other pharmaceutical enterprises. The company distributes its products through a diverse network, which includes retail pharmacy chains, wholesalers, distributors, mail-order pharmacies, and group purchasing organizations. Incorporated in 2001, its corporate headquarters are situated in Baudette, Minnesota.
ANIP Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 25 | Dec 24 | Dec 23 |
|---|---|---|---|
| Total Sales of Generics and Other | $399.41M | $320.03M | - |
| Sales of rare disease pharmaceutical products | $422.65M | $229.60M | $112.12M |
| Sales of Established Brands | $61.31M | $64.74M | - |
| Unapproved Products | - | $22.40M | - |
| Sales of established brand pharmaceutical products | - | - | $105.25M |
| Sales of generic pharmaceutical products | - | - | $269.45M |
Fiscal year ends in Dec 25 | Currency in USD